Clinical Trial Update: Buspirone as a Potential Treatment for Recurrent Central Apnea [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating buspirone for recurrent central sleep apnea in heart failure patients was terminated; results were posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Sleep Apnea
• Heart Failure

Drugs mentioned

• Buspirone (buspirone)

Snippet

Sponsor: VA Office of Research and Development | Conditions: Central Apnea, Heart Failure | Phase 3 | Status: TERMINATED | Results posted: 2016-03-14